Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89bio, Inc. - Common Stock (NQ:ETNB)

5.955 +0.065 (+1.10%)
Streaming Delayed Price Updated: 2:57 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 89bio, Inc. - Common Stock

< Previous 1 2 3 Next >
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
From 89bio, Inc.
Via GlobeNewswire
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
First FGF21 analog to enter Phase 3 development 
From 89bio, Inc.
Via GlobeNewswire
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/19
Via Investor Brand Network
89bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 4/10
Via Investor Brand Network
89Bio Inc. (NASDAQ: ETNB) is a Stock Spotlight on 3/31
Via Investor Brand Network
89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
89Bio Inc. (NASDAQ: ETNB) Records 52-Week High Friday Morning
Via Investor Brand Network
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
From 89bio, Inc.
Via GlobeNewswire
89Bio Inc. (NASDAQ: ETNB) Near the Top of Equities by Percentage Gain on 3/22
Via Investor Brand Network
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)
89bio, Inc. (NASDAQ: ETNB) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of 
Via Spotlight Growth
Exposures Product Safety
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
From 89bio, Inc.
Via GlobeNewswire
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the SVB Securities Global Biopharma Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Provides Business Update and Outlook for 2023
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.